Beta Bionics, Inc.

Beta Bionics maintains a strong liquidity position with $44.3 million in cash and equivalents against $36.0 million in total liabilities, resulting in a current ratio of 8.88 and a debt-to-equity ratio of 0.0. The company holds no long-term debt, relying entirely on equity financing to fund operations. However, the firm consumes cash rapidly, with operating cash flow at -$38.5 million and free cash flow at -$40.9 million for the six months ended June 30, 2026. This burn rate is driven by significant operating losses of -$49.8 million, which exceed net income losses of -$45.3 million due to non-operating items. The capital structure is pristine from a leverage standpoint but fragile from a cash-flow perspective, requiring continuous equity issuance or operational improvement to sustain solvency.

Profitability metrics remain deeply negative, with a return on equity of -28.55% and a return on assets of -25.04%. The gross profit of $35.3 million on $59.6 million in revenue indicates a gross margin of approximately 59.3%, which is typical for medical device companies but insufficient to cover the high fixed costs of research, development, and sales infrastructure. The operating loss of -$49.8 million highlights the pre-revenue scale nature of the business, where sales and marketing expenses, along with R&D, far outstrip gross contributions. Without cohort median data for direct comparison, the negative returns are consistent with early-stage commercialization firms in the healthcare sector that prioritize market penetration over immediate profitability.

Revenue generation is concentrated in the United States, with domestic operations forming the core of the business model. The company sells through multiple channels, including durable medical equipment distributors and pharmacy benefit plans, as indicated by filing references to specific distributor relationships and channel segments. The reliance on third-party distributors introduces concentration risk, as filings highlight customer concentration risks associated with specific distributors (e.g., Distributor A, B, C, D, E, F, G, H). The product mix includes both durable devices and single-use supplies, creating a recurring revenue component from consumables that supports long-term customer value. Geographic exposure is primarily domestic, with limited international presence disclosed in the financial statements.

Growth trajectory shows modest revenue expansion, with Q2 2026 revenue at $59.6 million. Comparing the six-month periods, revenue growth is evident but obscured by the lack of explicit prior-year revenue totals in the snapshot; however, the cash flow statements show a shift from significant investing outflows in 2025 (related to IPO proceeds deployment) to more normalized operating cash burns in 2026. The company completed its initial public offering in early 2025, raising substantial capital that is now being deployed into commercialization. The share count increased from approximately 43.5 million in mid-2025 to 45.0 million in mid-2026, reflecting dilution from stock-based compensation and employee stock purchase plans rather than new equity offerings.

Risk factors are dominated by dilution and liquidity concerns. The risk assessment flags medium dilution risk, supported by the issuance of common stock for employee stock purchase plans and stock option exercises. Filings explicitly mention risks related to the ability to forecast demand, regulatory developments, and reliance on single-source suppliers. The company also faces intellectual property risks and the challenge of maintaining regulatory approval for its products. Geopolitical and macroeconomic factors are cited as potential impacts on financial performance, though specific exposure is not quantified. The absence of debt mitigates interest rate risk but increases the pressure to generate positive cash flow to avoid further equity dilution.

Recent events include the filing of 8-K reports with material items related to results of operations and financial condition, indicating ongoing transparency with the market. Analyst sentiment is positive, with a mean price target of $20.08 and a median of $20.00, suggesting upside from the current market price of $12.83. The mean recommendation of 1.91 reflects a "buy" consensus, with four strong buys and four buys among the analysts covering the stock. The company continues to navigate the post-IPO landscape, focusing on scaling its sales and marketing organization while managing the cash burn associated with commercialization.

Analysts project 56.5% upside to a mean price target of $20.08, reflecting strong buy consensus among 11 analysts.

The company maintains a debt-to-equity ratio of 0.143, indicating low leverage and a conservative capital structure.

A current ratio of 8.66 suggests strong short-term liquidity, mitigating immediate solvency concerns despite operating losses.

Gross profit reached $55.5 million in FY2025, demonstrating the underlying profitability of the core product before operating expenses.

Liquidity risk is assessed as low, providing a buffer against short-term financial distress despite negative cash flows.

Free cash flow was negative $56.2 million in FY2025, indicating significant cash burn and reliance on external financing.

Medium dilution risk exists, potentially eroding shareholder value as the company seeks capital to fund operations.

Operating income declined to -$71.7 million in FY2025, widening the operating loss compared to prior periods.

Revenue $59.6M; Operating income -$49.8M.

• ▍Revenue $59.6M
• ▍Operating income -$49.8M
• ▍Net margin -76.0%

Revenue $27.6M; Operating income -$24.3M.

• ▍Revenue $27.6M
• ▍Operating income -$24.3M
• ▍Net margin -79.3%

Revenue $100.3M; Operating income -$71.7M.

• ▍Revenue $100.3M
• ▍Operating income -$71.7M
• ▍Net margin -73.0%

Revenue $65.1M; Operating income -$45.3M.

• ▍Revenue $65.1M
• ▍Operating income -$45.3M
• ▍Net margin -84.1%

Revenue $65.1M; Operating income -$45.3M.

• ▍Revenue $65.1M
• ▍Operating income -$45.3M
• ▍Net margin -84.1%

Revenue $12.0M; Operating income -$35.9M.

• ▍Revenue $12.0M
• ▍Operating income -$35.9M
• ▍Net margin -367.6%